Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

Completed · Phase 2 · Has a placebo group

Conditions studied: Respiratory Distress Syndrome, Adult

In brief

This Phase IIa pilot study is a placebo controlled, multicenter study to evaluate safety and efficacy of aerosolized BIO-11006 Inhalation Solution in ARDS patients. The subjects will be randomized 1:1 to either BIO-11006 125 mg twice daily plus standard of care or placebo plus standard of care. The treatment will continue for up to 28 days. The study will enroll up to 40 adult ARDS patients in up to eight sites within USA.

Key facts

Study ID

NCT03202394

Run by

BioMarck Pharmaceuticals, Ltd.

People needed

38

Starts

2017-08-05

Expected to finish

2020-06-15

Last updated by the study team

2020-06-25

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has provided (or relative has) written informed consent and authorization for use and disclosure of protected health information
• Has a clinical diagnosis of sepsis or septic shock defined as:
• Known or suspected infection
• Systemic inflammatory response syndrome (SIRS), defined as meeting at least 2 of the following 3 criteria for a systemic inflammatory response:
• White blood cell count >12,000 or <4,000 or >10% band forms
• Body temperature >38°C (any route) or <36°C (by core temperatures only: indwelling catheter, esophageal, rectal)
• Heart rate >90 beats/min or receiving medications that slow heart rate or pace rhythm
• Enrollment must occur within 48 hours of first meeting ARDS criteria per the Berlin definition of ARDS (ARDS Task Force 2012) and no more than 72 hours from the initiation of mechanical ventilation. (The bilateral opacities, respiratory failure, and decreased P/F ratio must all be present within a 24 hour time period of one another.):
• Lung injury of acute onset, within 1 week of an apparent clinical insult, with progression of respiratory symptoms
• Bilateral opacities on chest imaging not fully explained by effusions, lobar/lung collapse, or nodules.
• Respiratory failure not fully explained by cardiac failure or fluid overload. (Need objective assessment (e.g. echocardiography) to exclude hydrostatic edema if no risk factor present.)
• Decreased arterial partial pressure of oxygen (PaO2)/ fraction of inspired oxygen (FIO2) ratio while on a minimum Positive End Expiratory Pressure (PEEP) of 5 cm water (H2O):
• Moderate ARDS: 101 to 200 mmHg (≤ 26.6 kPa)
• Severe ARDS: ≤ 100 mmHg (≤ 13.3 kPa)

You may not qualify if…

• Age < 18 years or >75 years old
• Greater than 48 hours since first meeting ARDS criteria per the Berlin definition of ARDS
• Pregnant or breastfeeding (negative pregnancy test required prior to randomization for female patients of childbearing potential.)
• Prisoner
• Any other irreversible disease or condition for which 6 month mortality is estimated to be > 50%
• Moderate to severe liver failure (Child Pugh Score > 12)
• Severe chronic respiratory disease with a PaCO2 > 50 mmHg or the use of home oxygen
• Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest).
• Major trauma in the prior 5 days
• Lung transplant patient
• No consent/inability to obtain consent
• Moribund patient not expected to survive 24 hours
• World Health Organization (WHO) Functional Class III or IV pulmonary hypertension
• No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol
• Currently receiving extracorporeal life support or high frequency oscillatory ventilation
• Known hypersensitivity to BIO 11006
• Burn victims >20% Total Body Surface Area (TBSA) or with known airway inhalation injury

Where it is running

• University of Chicago Medicine — Chicago, Illinois, United States
• University of North Carolina School of Medicine — Chapel Hill, North Carolina, United States
• Wake Forest University — Winston-Salem, North Carolina, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Vanderbilt University, Div of Allergy, Pulmonary, Critical Care — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.